Down with Supplements! - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Down with Supplements!
FDA is buried in postapproval manufacturing submissions and seeks to reduce the scope of changes that require agency scrutiny.


Pharmaceutical Technology




To ensure drug quality throughout a product's life cycle, the US Food and Drug Administration requires manufacturers to report changes in processes or products that could have even a moderate effect on product performance or safety. Current regulations (21 CFR 314.70) set fairly strict guidelines for reporting postapproval changes. Companies file supplements even for routine revisions in raw materials, production processes, equipment, and facilities if there is any chance a change will affect product quality. Only a relatively short list of changes that have "minimal" potential for harm can be submitted to the agency after the fact in an annual report.


Jill Wechsler
FDA consequently is swamped with postmarketing submissions. Industry filed some 6000 supplements for new drugs, biologics, and generics last year. About 2000 involve "major" changes that require FDA prior approval before a company can distribute drugs produced by the altered system (see sidebar, "Sorting out supplements"). The supplement volume has grown steadily and may accelerate more as industry mergers and reorganizations lead to plant closings and shifts to new manufacturing sites and processes.

Risk and quality


In Washington This Month
The task of preparing and filing supplements is a huge burden for industry and FDA. Consequently, manufacturers think twice about upgrading equipment or revising processes, even if it means forgoing opportunities to modernize outdated systems and improve formulations. That reluctance runs counter to FDA's initiative to modernize current good manufacturing practices (CGMPs) for the 21st century, which encourages manufacturers to adopt modern quality-control tools and systems able to ensure consistent product quality, safety, and efficacy. FDA advocates a quality-by-design (QbD) approach for achieving the "desired state" of quality drug manufacturing—one in which companies apply extensive knowledge about critical product and process parameters and quality attributes to achieve continuous improvement throughout the product life cycle.

This CGMP-modernization initiative is five years old and provides a framework for taking a new look at manufacturing-supplement filing requirements. FDA acknowledges that its current policy reflects a desire for "extensive control over virtually every aspect of the manufacturing process," according to the announcement of a February public meeting to discuss agency proposals for revising policies governing supplements and manufacturing changes. Companies adopting QbD approaches ideally would be rewarded with reduced regulatory oversight in terms of modified manufacturing supplement filing requirements and less-frequent plant inspections.

New approaches

FDA officials consequently are looking for ways to reduce the volume of supplements involving relatively low-risk changes to process and product. That involves considering how a manufacturer's internal change-control system may allow more manufacturing modifications to be made without FDA prior approval or oversight, explained Jon Clark, deputy director for policy at the Office of Pharmaceutical Science (OPS) in the Center for Drug Evaluation and Research (CDER).

Instead of a prescriptive and rules-based approach, FDA wants to leverage advances in manufacturing science to reduce the need to review low-risk manufacturing changes. Manufacturers would gain more flexibility to make timely, low-risk improvements in processes, and FDA would make more efficient use of its resources by not having to review many supplements. A risk-based approach to postmarketing regulation also would permit agency staffers to focus oversight on those changes most likely to have serious consequences for product safety and quality.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here